This is the authors' abstract. We don't add key points for this paper.
Aim The incidence of young-onset rectal cancer (YORC) is increasing. Treatment often includes pelvic radiation, which can affect bone and vaginal health and induce menopause in women. Estrogen can treat vasomotor symptoms of menopause, as well as support bone and vaginal health. We aimed to characterize rates of estrogen prescriptions for women with YORC.Methods We retrospectively reviewed records of all women with YORC treated with pelvic radiation between January 1, 2000, and April 1, 2022. Patient characteristics, bone health and sexual health outcomes were compared between those who were and were not prescribed estrogen.Results Of 183 women, 106 (57.9%) were prescribed estrogen. Women prescribed estrogen were younger (43 [37–47] vs 44 [42–47]; P=.01) and more often non-Hispanic (98 (92.5%) vs 63 (81.8%); P=.03). Only 129 (70.5%) women were sexually active at last follow-up. There were no differences in bone or sexual function outcomes, but more women who received estrogen were sexually active (89 (84.0%) vs 40 (51.9%); P<.01).Conclusion Less than 60% of women were prescribed estrogen after pelvic radiation for YORC, potentially indicating a gap in care. Further work is needed to define best practices for supporting bone health, sexual health and quality of life during survivorship.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Arzola et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: